Novakand Pharma AB (publ) is a Swedish biotechnology company specializing in the research and development of pharmaceutical drug candidates. Established in 2010 and headquartered in Solna, the company focuses primarily on developing treatments for severe inflammatory diseases and cancer. Its key programs involve the Fractalkine pathway, with drug candidates targeting inflammatory conditions and various cancers, including ovarian cancer and hematological malignancies. With a workforce of a few dedicated employees, Novakand Pharma acts as an innovator within the health technology and major pharmaceuticals sector, advancing small molecule therapeutics through clinical development stages. The company’s role in the financial market is that of a specialized biotech firm whose value proposition centers on its pipeline projects and potential contributions to treating serious diseases, thereby influencing investor interest in progressing pharmaceutical innovations.